Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 1,851 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Active, not recruiting Phase 1 Interventional

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

NCT06928246
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Onabotulinum Toxin Type A - Phase 1b, Onabotulinum Toxin Type A - Phase 2
Drug
Lead sponsor
Daniel Kaplan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Care After Inherited Cancer Testing

NCT04763915
View directory record Official record
Conditions
Inherited Cancer Syndrome, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Breast Cancer
Interventions
Correlative Studies (Survey), Correlative Studies (Interview), GeneSHARE, LivingLabReport, Standard-of-care & Adaptive Intervention, Access to Education Materials
Other · Behavioral
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nourishing Hair, Skin & Nails Supplement Study (Derm Aid)

NCT04249128
View directory record Official record
Conditions
Hair Loss, Skin Laxity, Cosmetic Acne, Nails; Soft, Skin Aging
Interventions
Vegetarian Collagen, Keratin, Ceramides, Astaxanthin
Dietary Supplement
Lead sponsor
ProofPilot
Industry
Eligibility
26 Years to 100 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 31, 2026, 1:34 PM EDT
Not listed Not applicable Interventional

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

NCT01921309
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, CDH
Interventions
Trinity CoC Total Hip System, Trinity Ceramic-on-Poly THR
Device
Lead sponsor
Corin
Industry
Eligibility
18 Years to 80 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
9
States / cities
Little Rock, Arkansas • Parker, Colorado • Hartford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis

NCT02975206
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
13 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
52
States / cities
Anniston, Alabama • Birmingham, Alabama • Hoover, Alabama + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Community-based Assessment of Skin Care, Allergies, and Eczema

NCT03409367
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions
Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Day to 63 Days
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

NCT03346434
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • Gilbert, Arizona • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

NCT00883311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BRT-FC-83C
Device
Lead sponsor
Biomed Research & Technologies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

NCT00879944
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Blood pressure, Height, Weight, BMI, Waist Circumference
Other
Lead sponsor
Northwestern University
Other
Eligibility
5 Years to 17 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
9
States / cities
San Diego, California • San Francisco, California • Stanford, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage

NCT00991198
View directory record Official record
Conditions
Rosacea, Acne Vulgaris, Atopic Dermatitis, Seborrheic Dermatitis
Interventions
Topical oxygen, placebo
Drug
Lead sponsor
Aria Aesthetics Inc.
Industry
Eligibility
25 Years to 60 Years · Female only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sweat Duct Imaging in Mother/Newborn Dyads

NCT01342133
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
Not listed
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Results available

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

NCT03775434
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Experimental: B244
Drug
Lead sponsor
AOBiome LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Bryant, Arkansas • Los Angeles, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Phase 3 Interventional

Clinical Trial to Compare the Efficacy of Celiprolol to Placebo in Patients With Vascular Ehlers-Danlos Syndrome

NCT05432466
View directory record Official record
Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
ACER-002 (celiprolol) 200 mg BID, Placebo BID
Drug
Lead sponsor
Acer Therapeutics Inc.
Industry
Eligibility
15 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

NCT05206331
View directory record Official record
Conditions
Breast Cancer
Interventions
contrast enhanced mammography, Iodinated Contrast Media (ICM)
Device · Drug
Lead sponsor
Margarita Louise Zuley
Other
Eligibility
30 Years and older · Female only
Enrollment
2,089 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Not listed No phase listed Observational

Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00005900
View directory record Official record
Conditions
I Cell Disease, Fucosidosis, Globoid Cell Leukodystrophy, Adrenoleukodystrophy, Mannosidosis, Niemann-Pick Disease, Pulmonary Complications, Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Metachromatic Leukodystrophy, Gaucher's Disease, Wolman Disease
Interventions
Not listed
Lead sponsor
Fairview University Medical Center
Other
Eligibility
0 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 1:34 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Skin and Serum Carotenoids in Preterm Infants Fed on a Formula Supplemented With Carotenoids

NCT00872664
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
carotenoids
Dietary Supplement
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Days
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

NCT05302921
View directory record Official record
Conditions
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Melanoma, Hepatoblastoma, Hepatocellular Carcinoma, Neuroblastoma, Wilms Tumor
Interventions
Cryoablation Therapy, Nivolumab, Ipilimumab
Procedure · Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
1 Year to 39 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle GI Health RDH™: A Study Assessing the Impact of Health and Wellness Products on Gastrointestinal (GI) Health and Related Health Outcomes

NCT07230821
View directory record Official record
Conditions
Gas and Bloating, Diarrhea, Constipation
Interventions
GI Health Active Product 1, GI Health Product Placebo Control
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational

Skin Fluorescent Imaging (SFI) System in Patients With Nevi

NCT04368247
View directory record Official record
Conditions
Nevus, Dysplasia; Epithelial
Interventions
Skin Fluorescent Imaging
Diagnostic Test
Lead sponsor
Orlucent, Inc
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Timeline
2020 – 2023
U.S. locations
4
States / cities
Fremont, California • Northridge, California • Vallejo, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Interferon Responses in Eczema Herpeticum

NCT01429311
View directory record Official record
Conditions
Atopic Dermatitis, Eczema Herpeticum, Herpes Simplex Infections, Eczema Vaccinatum
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03985943
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
57
States / cities
North Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 31, 2026, 1:34 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa, idursulfase
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 31, 2026, 1:34 PM EDT